Other Biopharmaceuticals

Kyowa Kirin Co., Ltd.

Kawaglyn Co. Halts Rokaltinib Monoclonal Antibody Clinical Trial

4151

Kyowa Kirin's stock has seen mixed performance, with a 1.9% increase over the past week but a 5.7% decline year-to-date. The company is currently undervalued by 11.6% according to a Discounted Cash Flow analysis, with a projected intrinsic value of ¥2,680.78 per share. Its P/E ratio stands at 17.02x, slightly above the industry average, indicating it is trading below its fair value. Investors are encouraged to explore different narratives for a clearer valuation perspective.

Simplywall

Nano Labs

Is Kyowa Kirin (TSE:4151) Pricing Reflect Its Mixed Long Term Share Performance

Kyowa Kirin has received FDA approval for an updated dosing regimen of Crysvita, a treatment for X-linked hypophosphatemia (XLH). The new guidelines allow healthcare providers to increase the dose and frequency for patients with low serum phosphorus levels. Crysvita, a monoclonal antibody, targets FGF23 to improve phosphorus retention and vitamin D levels. This update aims to provide a more personalized treatment approach for XLH patients, enhancing their care options.

Pharmaceutical Technology

Kyowa Kirin secures FDA approval for Crysvita dosing update

KURA

ARKG

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress | KURA Stock News

StockTitan

Kura Oncology

iShares Biotechnology ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VG Health

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

iShares US Pharma

SPDR S&P Biotech

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress  | KURA Stock News

Kyowa Kirin and Kura Oncology have initiated a Phase II trial of ziftomenib for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukaemia (AML) in Japan. The trial aims to assess the efficacy and safety of ziftomenib, with a primary endpoint of composite complete remission rate. Following the trial, Kyowa Kirin plans to seek regulatory approval in Japan. Ziftomenib, approved by the FDA in November 2025, offers a new treatment option for patients with limited alternatives.

WorldPharmaceuticals

Kyowa Kirin and Kura initiate Phase II trial of ziftomenib for AML

Amgen and Kyowa Kirin have halted all clinical trials of rocatinlimab due to newly identified safety risks, including malignancy cases. This decision removes a significant immunology asset from Amgen's pipeline. Currently, Amgen's stock trades at $349.92, with a 1-year return of 14.6% and a 5-year return of 66.2%. The discontinuation raises questions about R&D spending and future program replacements. Analysts note the share price is close to the consensus target of $350.55, but recent declines indicate weak momentum. Investors should monitor how this impacts Amgen's research focus and financial health.

Amgen

Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation

2503

Kirin Holdings Company (TSE:2503) is gaining attention after its subsidiary Kyowa Kirin partnered with Cowellnex and Metagen to develop gut microbiota health solutions. The company has seen an 8.44% share price increase over 30 days and a 29.85% return over the past year. With a P/E ratio of 14.2x, below industry averages, Kirin appears undervalued compared to its estimated fair value of ¥4,545 per share. However, risks remain if earnings decline or the health initiative falters. Investors are encouraged to explore further opportunities in undervalued stocks.

Kirin Holdings Company, Limited

Assessing Kirin Holdings Company (TSE:2503) Valuation After New Gut Microbiota Health Collaboration

Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody. This decision follows a safety review that raised concerns about potential risks, including malignancies linked to the treatment. Despite previous efficacy in moderate-to-severe atopic dermatitis, the evolving safety profile led to the conclusion that risks may outweigh benefits. Both Kyowa Kirin and Amgen will notify regulatory authorities and terminate studies after safety follow-ups are completed.

Kyowa Kirin discontinues ongoing trials of rocatinlimab

Kyowa Kirin Co., Ltd.(4151.JP)